Loading clinical trials...
Loading clinical trials...
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. * Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples. * Correlation analysis of KRAS mutation results with clinical data. Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. * Gene panel composition for pancreatic cancer therapeutic target determination and monitoring. * A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients. * Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
Age
All ages
Sex
ALL
Healthy Volunteers
No
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
Goyang-si, Gyeonggi-do, South Korea
Start Date
March 28, 2019
Primary Completion Date
June 3, 2021
Completion Date
December 31, 2025
Last Updated
June 19, 2025
420
ACTUAL participants
Lead Sponsor
National Cancer Center, Korea
NCT07282912
NCT05825066
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions